[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100285367":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":10,"centralContacts":42,"locations":48,"responsibleParty":63,"collaborators":10,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":10,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":10,"studyType":81,"phases":10,"briefSummary":82,"conditions":83,"keywords":10,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Beth Israel Deaconess Medical Center","OTHER",[8,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Neurological Disease subjects",null,"Parkinson's Disease and other Parkinsonian Disorders subjects. Other Parkinsonian Disorders include Atypical Parkinsonism such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Primary Gait Freezing Disorder, Indeterminate Parkinsonian Syndrome. During the first visit no intervention will take place. There is an optional second visit during which subjects with Parkinson's Disease are asked to come come off antiparkinson medication and if applicable, off both medication and deep brain stimulation.",[13,14],"Drug: Anti-Parkinson medication","Device: Deep Brain Stimulation",{"label":16,"type":10,"description":17,"interventionNames":10},"Healthy control subjects","The healthy control subjects will be age- and sex-matched to the Neurological Disease subjects.",{"label":19,"type":10,"description":20,"interventionNames":10},"Ataxia Subjects","The ataxia subjects will participate in an additional cohort that will test and validate the gait model.",{"label":22,"type":10,"description":23,"interventionNames":10},"Huntington Disease Subjects","The Huntington Disease subjects will participate in an additional cohort that will test and validate the gait model.",[25,37],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Anti-Parkinson medication","During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.",[9],[31,32,33,34,35,36],"Carbidopa\u002Flevodopa","pramipexole","ropinirole","amantadine","tolcapone","entacapone",{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"DEVICE","Deep Brain Stimulation","During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.",[9],[43],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":47},"Veronique Vanderhorst, MD PhD","CONTACT","617-667-0519","vvanderh@bidmc.harvard.edu",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":10},"Clinical Research Center BIDMC","RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-71.05977,42.35843,{"lat":61,"lon":60},{"type":64,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Veronique Vanderhorst","Associate Professor of Neurology","100285367","gait-analysis-in-neurological-disease-100285367",false,"NCT02994719","Gait Analysis in Neurological Disease","Gait Pattern Analysis in Neurological Disease","Inclusion Criteria:\n\n* Age 18-85 (for both healthy and affected subjects).\n* Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural instability (UK PD Brain Bank Criteria) (Affected subjects only).\n* Montreal Cognitive Assessment will be employed to determine whether subjects will need the assent of a legally authorized representative. Subjects with MOCA ≤ 21 will be consented only with the assent of the subject and informed consent of the authorized legal representative (Affected subjects only).\n* These may include subjects who may have indeterminate parkinsonism, when it is not clear whether they have idiopathic Parkinson's Disease versus one of the Atypical Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration (Affected subjects only).\n* Subjects with assistive devices will be eligible for the study and may use them during the study (Affected subjects only).\n* Absence of complaints regarding difficulty walking such as arthritic pain, fatigue during walking or slowness of walking (Healthy subjects only).\n\nExclusion Criteria:\n\n* Presence of alternative explanation for parkinsonism such as head trauma, drug-induced parkinsonism (affected subjects only).\n* Currently being treated for major medical illness requiring recent hospitalization (\\\u003C14 days) (for both healthy and affected subjects).\n* Currently participating in another clinical study with an intervention arm (for both healthy and affected subjects).\n* Inability to consent due to cognitive impairment and absence of legally authorized representative (for both healthy and affected subjects).\n* Subjects with any cardiac, pulmonary conditions (congestive heart failure requiring hospitalization within the past 90 days, recent myocardial infarction \\\u003C 90 days, supplemental oxygen-requiring subjects due to cardiac or pulmonary conditions) that limit their ability to safely participate in a walking trial (for both healthy and affected subjects).",true,"ALL","18 Years","85 Years",{"count":79,"type":80},120,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to investigate whether speed-dependent measures of gait can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.",[84,85,86,87,88,89,90,91],"Parkinson's Disease","Parkinsonian Disorders","Atypical Parkinson Disease","Progressive Supranuclear Palsy","Multiple System Atrophy","Corticobasal Degeneration","Gait, Frontal","Huntington Disease","2025-06-05",{"date":94,"type":95},"2025-06-08","ACTUAL",{"date":97,"type":95},"2016-03-01",{"date":99,"type":80},"2026-06-20",{"name":5,"class":6},1]